NZ252738A - Desferrioxamine-b salts; medicaments - Google Patents

Desferrioxamine-b salts; medicaments

Info

Publication number
NZ252738A
NZ252738A NZ252738A NZ25273893A NZ252738A NZ 252738 A NZ252738 A NZ 252738A NZ 252738 A NZ252738 A NZ 252738A NZ 25273893 A NZ25273893 A NZ 25273893A NZ 252738 A NZ252738 A NZ 252738A
Authority
NZ
New Zealand
Prior art keywords
salt
sulphonic acid
formula
methanesulphonate
water
Prior art date
Application number
NZ252738A
Other languages
English (en)
Inventor
Nicholas Lowther
Ian Francis Hassan
Ian Timothy William Matthews
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NZ252738A publication Critical patent/NZ252738A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ252738A 1992-06-03 1993-05-06 Desferrioxamine-b salts; medicaments NZ252738A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929211779A GB9211779D0 (en) 1992-06-03 1992-06-03 Amine salts

Publications (1)

Publication Number Publication Date
NZ252738A true NZ252738A (en) 1996-08-27

Family

ID=10716488

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ252738A NZ252738A (en) 1992-06-03 1993-05-06 Desferrioxamine-b salts; medicaments

Country Status (16)

Country Link
US (2) US5739167A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0643690B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH07507288A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR950701907A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE166342T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU672607B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2135394A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69318711T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0643690T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2117132T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI945654A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB9211779D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO302749B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ252738A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW230203B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1993024451A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2414214C2 (ru) * 2003-06-06 2011-03-20 Фиброген, Инк. Применение стабилизаторов hif-альфа для усиления эритропоэза
US8604012B2 (en) 2003-06-06 2013-12-10 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR009655A1 (es) * 1996-12-10 2000-04-26 Novartis Ag Una composicion parenteralmente inyectable, un metodo para su preparacion, metodos para el tratamiento de enfermedades, una modificacion decristal de 1-decansulfonato de desferrioxamina, su uso, un proceso para la produccion de dicha modificacion de cristal y una preparacion farmaceutica que
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
GB9727224D0 (en) * 1997-12-23 1998-02-25 Nycomed Imaging As Method
US6323218B1 (en) 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US6958161B2 (en) * 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
US8236783B2 (en) * 2006-08-15 2012-08-07 Duke University ROS-sensitive iron chelators and methods of using the same
US9139456B2 (en) 2008-04-16 2015-09-22 The Curators Of The University Of Missouri Chelating compounds and immobilized tethered chelators
US9259670B2 (en) 2008-04-16 2016-02-16 The University Of Kentucky Research Foundation Flow-through filter to remove aluminum from medical solutions
US7932326B2 (en) * 2008-04-16 2011-04-26 The University Of Kentucky Research Foundation Chelating compounds and immobilized tethered chelators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH438351A (de) * 1959-09-25 1967-06-30 Ciba Geigy Verfahren zur Herstellung neuer Wuchsstoffe
FR1898M (fr) * 1961-04-07 1963-07-08 Ciba Geigy Nouvelle substance utilisable en thérapeutique.
US3679660A (en) * 1969-06-09 1972-07-25 Agatha C Magnus Glucosamine-alkylsulfonate and process
US3652411A (en) * 1969-12-04 1972-03-28 Mobil Oil Corp Polyglycol base lubricant
US4419365A (en) * 1981-12-21 1983-12-06 Ciba-Geigy Corporation Method of treating Alzheimer's disease
US4684482A (en) * 1984-01-26 1987-08-04 Oral-D (L.P.) Orally effective ion chelators
IT1173992B (it) * 1984-05-16 1987-06-24 Bioresearch Spa Sali stabili della solfo-adenosil-l-metionina (same) particolarmente idonei per uso farmaceutico orale
MX12394A (es) * 1987-07-23 1993-12-01 Ciba Geigy Ag Procedimiento par la obtencion de carbamatos de polietilenglicol.
WO1992020227A1 (en) * 1991-05-13 1992-11-26 Oral-D Substituted orally effective ion chelators related to deferoxamine

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2414214C2 (ru) * 2003-06-06 2011-03-20 Фиброген, Инк. Применение стабилизаторов hif-альфа для усиления эритропоэза
US8604012B2 (en) 2003-06-06 2013-12-10 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US8604013B2 (en) 2003-06-06 2013-12-10 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US8609646B2 (en) 2003-06-06 2013-12-17 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US8629131B2 (en) 2003-06-06 2014-01-14 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US9920011B2 (en) 2003-06-06 2018-03-20 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US10626090B2 (en) 2003-06-06 2020-04-21 Fibrogen Inc. Enhanced erythropoiesis and iron metabolism
US10882827B2 (en) 2003-06-06 2021-01-05 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US10894774B2 (en) 2003-06-06 2021-01-19 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US10927081B2 (en) 2003-06-06 2021-02-23 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US11680047B2 (en) 2003-06-06 2023-06-20 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US11680048B2 (en) 2003-06-06 2023-06-20 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism

Also Published As

Publication number Publication date
DK0643690T3 (da) 1999-01-25
AU672607B2 (en) 1996-10-10
TW230203B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1994-09-11
ES2117132T3 (es) 1998-08-01
ATE166342T1 (de) 1998-06-15
HK1009330A1 (en) 1999-05-28
NO944617L (no) 1995-01-05
GB9211779D0 (en) 1992-07-15
US5663201A (en) 1997-09-02
AU4270093A (en) 1993-12-30
DE69318711D1 (de) 1998-06-25
JPH07507288A (ja) 1995-08-10
CA2135394A1 (en) 1993-12-09
US5739167A (en) 1998-04-14
NO302749B1 (no) 1998-04-20
DE69318711T2 (de) 1998-11-19
FI945654A7 (fi) 1994-11-30
FI945654A0 (fi) 1994-11-30
NO944617D0 (no) 1994-12-01
WO1993024451A1 (en) 1993-12-09
EP0643690A1 (en) 1995-03-22
KR950701907A (ko) 1995-05-17
EP0643690B1 (en) 1998-05-20

Similar Documents

Publication Publication Date Title
EP0643690B1 (en) Desferrioxamine-b salts and their use as orally effective iron chelators
JPH0811729B2 (ja) １−ヒドロキシピリド−２−オン、又はその塩から成る、患者の体内になる毒性レベルの金属を減少させるのに有効な医薬組成物
US4812590A (en) Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
US2823164A (en) Method of preparing 3, 5, 3' l-tri-iodothyronine and pharmaceutical compositions thereof
AU599034B2 (en) Furosemide salts
US4455305A (en) Composition for the treatment of colitis ulcerosa, enteritis regionalis crohn (morbus crohn), chronic nonspecific colitis and diverticulitis and the use of salicylazobenzoic acid for the preparation of such compositions
FI113642B (fi) Menetelmä tilidiinidivetyortofosfaatin valmistamiseksi
AU685408B2 (en) Combination of atovaquone with proguanil for the treatment of protozoal infections
NZ204017A (en) 4-aminohepta-5,6-dienoic acid derivatives and pharmaceutical compositions
US4973553A (en) Salt or organogermanium compound and medicine containing the same
HK1009330B (en) Desferrioxamine-b salts and their use as orally effective iron chelators
US4029666A (en) Benzenesulfonyl-ureas and process for preparing them
US4131678A (en) Urapidil/furosemide compounds, compositions and use
US4421768A (en) Fluorinated diamino-heptene and-heptyne derivatives
US4562206A (en) Orally effective inotropic compounds
CA2009709A1 (en) Derivatives of 3-pyroglutamyl-thiazolidine-4-carboxylic acid and their pharmacological properties
KR890000795B1 (ko) 플루오르화 디아미노-헵텐 및 -헵틴 유도체 및 이의 제조방법
JPS59508B2 (ja) ノウケツカンカクチヨウザイ ２ ３− チカン −４− フクソカンジヨウアミノスルホニルベンゼンスルホンアミド ノ セイホウ
US3792034A (en) Tripeptide and acid addition salts
US4521424A (en) Quinate salts of the antimalarial compound mefloquine
EP0153171A2 (en) New 2-hydroxyethyl-trimethylammonium salt of 1-ethyl-3-carboxy-4-oxo-6,7-methylenedioxy-1,4-dihydroquinoline, process for the preparation thereof and pharmaceutical composition containing it
NZ209519A (en) 1--3- aminopropanol derivatives and pharmaceutical compositions
WO2005023789A1 (en) Phosphoric acid salt of (s)-(+)-2-ethoxy-4-{[3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoic acid
JPH0338252B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO2005023790A1 (en) (s)-(+)-2-ethoxy-4-{[3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoic acid sodium salt